Table 4.
Maternal outcomes between the TDF treatment and control groups.
| TDF Group Mean ± SD or n (%) | Control Group Mean ± SD or n (%) | p | |
|---|---|---|---|
| Mothers | |||
| Pregnancy weeks | 39.46 ± 1.43 | 39.33 ± 1.49 | 0.645 |
| Cesarean section, n (%) | 21 (36.2%) | 17 (32.7%) | 0.699 |
| Obstetric complications, n (%) | |||
| Pregnancy hypertension | 0 | 0 | |
| Placenta previa | 0 | 0 | |
| Intrahepatic cholestasis of pregnancy | 6 (10.3%) | 5 (9.6%) | 0.899 |
| Postpartum hemorrhage | 0 | 0 | |
| Limited fetal growth | 0 | 0 | |
| Preterm birth | 1 (1.69%) | 2 (3.85%) | 0.495 |
| Abortion | 1 (1.72%) | 0 | 0.342 |
| Adverse reactions, n (%) | |||
| Digestive tract reaction: vomiting | 2 (3.45%) | 0 | 0.177 |
| Fatigue | 0 | 0 | |
| Headache | 0 | 0 | |
| Cough | 0 | 0 | |
| Fever | 0 | 0 | |
| Itchy skin | 6 (10.3%) | 5 (9.6%) | 0.899 |
| Jaundice | 0 | 0 | |
| Laboratory examinations, n (%) | |||
| ALT, U/L >5 × ULN* | 2 (3.45%) | 0 | 0.177 |
| Renal dysfunction | 0 | 0 | |
| Decrease of PLT | 0 | 0 | |
| Anemia | 0 | 0 | |
*ULN: upper limit of normal.